Luye Pharma
绿叶制药
Executive Summary
Luye Pharma is a Hong Kong-listed Chinese pharmaceutical company headquartered in Yantai, specializing in innovative drug delivery systems and CNS therapeutics. The company has demonstrated strong commercial execution with global expansion capabilities and maintains an active BD posture for international partnerships. BIOSECURE risk appears low given clear designation status, making them a viable partner for US pharma deals. Limited public information on recent corporate activities suggests potential need for deeper due diligence on current pipeline status.
Structure: As a Hong Kong-listed entity (2186.HK), Luye Pharma likely operates through a typical offshore holding structure with mainland Chinese operating subsidiaries. The Yantai headquarters suggests significant onshore operations that would require VIE structure analysis during due diligence. Standard Hong Kong listing framework should facilitate regulatory transparency for US partnership evaluations.
BIOSECURE Risk
Company shows clear BIOSECURE status with no BCC designation, indicating minimal regulatory restrictions for US partnerships
Key Exposures:
- •Mainland China manufacturing operations
- •Potential supply chain dependencies
- •Data handling protocols for clinical trials
Mitigation: Clear regulatory status suggests existing compliance framework, though specific mitigation strategies not publicly documented
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity recorded in available data - requires further investigation
Approach: Approach with standard due diligence protocols focusing on pipeline depth assessment and manufacturing capabilities validation
Red Flags
- ⚠Limited public disclosure of recent corporate activities
- ⚠Absence of visible senior leadership profiles
- ⚠No recorded recent partnership or licensing deals
- ⚠Insufficient subsidiary structure transparency
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.